Understanding a drug’s pharmacokinetic (PK) profile is essential to evaluating its efficacy and safety. Avantia Labs provides comprehensive PK assay development, validation, and testing, delivering dependable pharmacokinetic data to guide dose selection, administration route, and study design across preclinical and clinical programs.

Pharmacokinetic (PK) studies provide critical insight into how a drug is absorbed, distributed, metabolized, and excreted by the body. Through advanced PK assay techniques and robust pharmacokinetic analysis, Avantia Labs helps researchers interpret exposure profiles, optimize dosing strategies, and ensure data integrity across all stages of biologic and small-molecule drug development.

Our biomarker assay services support every stage of drug development, from discovery to clinical evaluation. Avantia Labs offers customized assay development, validation, and quantitative analysis to measure pharmacodynamic responses, confirm target engagement, and assess treatment efficacy with precision and regulatory compliance.

Biomarkers play a crucial role in understanding drug efficacy, safety, and mechanism of action. At Avantia Labs, we provide customized biomarker assay development, validation, and analysis to support both preclinical and clinical studies. Our expertise spans protein, genomic, and cell-based biomarkers, delivering accurate, regulatory-compliant data to guide informed decisions throughout biologic and gene therapy development.

Avantia Labs is a specialized bioanalytical CRO offering PK, ADA, MAPPs, biomarker, and cell-based assay services. Our scientists combine deep technical expertise with advanced analytical platforms to deliver high-quality, regulatory-compliant data that support biologic, gene, and cell therapy development from early discovery through clinical trials.

We believe in building lasting partnerships through scientific excellence, transparency, and quality-driven results. Every study is designed with precision and compliance in mind, ensuring audit-ready data and actionable insights that accelerate decision-making and reduce development risk — helping clients move confidently from lab to clinic.

Avantia Labs provides comprehensive bioanalytical solutions to support the development of cell and gene therapy (CGT) products from discovery through clinical stages. Our scientists specialize in precise quantification of gene and vector targets using ddPCR and qPCR, ensuring accurate measurement of transgene expression, vector copy number, and biodistribution.

We also perform functional and potency assays to evaluate therapeutic activity, including ELISpot, flow cytometry, and cell-based assays that characterize immune responses and cellular functionality. With validated platforms, regulatory compliance, and scientific expertise, Avantia delivers reliable data to accelerate safe and effective CGT development.

Avantia Labs offers comprehensive anti-drug antibody (ADA) and neutralizing antibody (NAb) assay development and validation to support biotherapeutic immunogenicity assessment. Our experienced scientists design and optimize assays using platforms such as MSD, ELISA, and cell-based functional assays, ensuring high sensitivity, specificity, and reproducibility across all study phases.

From screening to confirmatory and titer determination, we provide end-to-end support that meets GLP/GCLP standards and regulatory expectations. Whether you require customized assay design or validation of existing methods, Avantia Labs delivers reliable, data-driven solutions to evaluate immune responses and ensure the safety and efficacy of your biologic products.